Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+proteins

33 Results

Sort By:

Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases

C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...

Published: 1/22/2026 | Inventor(s): Niranjan Pandey, Elena Rosca, Corban Rivera, Jacob Koskimaki, Amir Tamiz, Aleksander Popel

Keywords(s): Biologics, Cancers, Disease Indication, Peptide, Protein, Single, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

A method for inhibiting UHRF1 in colorectal cancer

Value PropositionReversal of colorectal cancer-specific DNA hypermethylationmRNA-based strategy for UHRF1 inhibitionA lipid nanoparticle-based delivery platformUnmet Need1 out of 24 people will develop colorectal cancer. Current technologies do not maximize the bodies’ native ability to suppress tumors. Existing therapies lack specificity and cause...

Published: 1/22/2026 | Inventor(s): Stephen Baylin, Srinivasan Yegnasubramanian, Ying Cui, Xiangqian Kong

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Research Tools > Proteins, Ligands & Receptors

A Method to Conditionally Deliver Effector Proteins to Plasma and Endosomal Membranes in Response to Tyrosine Kinase Signaling

Value Proposition· Effective & Targeted: Harnesses endogenous pain signaling via receptor tyrosine kinases to conditionally deliver effector proteins to the plasma membrane, enabling suppression of chronic pain under pathological conditions· Broadly Applicable: Enables modular, tunable therapy tailored to the prevailing pathological...

Published: 1/22/2026 | Inventor(s): Michael Caterina, Stephen Gould, Shang-Jui Tsai

Keywords(s):

Category(s): Clinical and Disease Specializations > Pain > Chronic Pain, Technology Classifications > Therapeutic Modalities > Proteins, Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Oncology

Method for Surface Expression of Membrane Proteins that have a Cytoplasmic C-terminal Tail

Enhanced Vaccine Development through Optimized Antigen DisplayJHU Ref #: C16777Value Proposition· Improved antigenicity due to increased cell surface expression of viral proteins · Boosts vaccine efficacy · Potential for integration into various vaccine platforms, including viral-mediated, mRNA-mediated, and DNA-mediated vaccines Unmet...

Published: 1/22/2026 | Inventor(s): Stephen Gould, Linda Marban, Chenxu Guo, Shang-Jui Tsai

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Vaccines

mRNA Intensifier to treat Haploinsufficiencies

Unmet Need / Invention Novelty: Haploinsufficiency occurs when one gene allele is inactivated and the amount of gene product expressed from the remaining active allele is insufficient for proper gene function. Targeted restoration of mRNA expression and translation may offer a therapeutic window. Technical Details: Johns Hopkins researchers designed...

Published: 1/22/2026 | Inventor(s): Jeffery Coller, Bahareh Torkzaban

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins

Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same

Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...

Published: 1/22/2026 | Inventor(s): Hai-Quan Mao, Stephany Tzeng, Jordan Green, Yizong Hu, Sashank Reddy, Leonardo Cheng

Keywords(s):

The Efficacy of Nanozyme in Neurodegenerative Diseases

Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...

Published: 1/22/2026 | Inventor(s): Xiaobo Mao, Shuya Li, Weiwei He

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Therapeutic Modalities > Proteins

Transgenic Fungi that Kill Malaria Parasites in Mosquitoes

Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...

Published: 1/22/2026 | Inventor(s): Raymond St. Leger, Angray Kang, Weiguo Fang, Marcelo Jacobs-Lorena

Keywords(s): Biologics, Disease Indication, Disease Management System, Healthcare Management, Infectious Diseases, Malaria, Operations Management, Parasitic Infections, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Computers, Electronics & Software, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections

Identification of TDP-43 Cryptic Exons as Functional Fluid Biomarkers for Alzheimer's Disease and Related Dementia

JHU C16735Unmet Need: TDP-43 (Tar DNA-binding protein 43) acts as a guardian of the transcriptome by repressing the splicing of non-conserved, unannotated cryptic exons. Loss of TDP-43 function causes neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Limbic-Predominant Age-Related TDP-43 Encephalopathy...

Published: 1/22/2026 | Inventor(s): Philip Wong, Jonathan Ling

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Proteins, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Dementia

Mutant Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH): A Novel Anticancer Therapeutic for Solid Malignancies

Unmet Need: One of the hallmarks of cancer cells is metabolic reprogramming for faster metabolism and cell growth. For example, increased glycolysis has long been known to be part of cancer cells’ biochemical adaptation. One of the key enzymes of glycolysis is glyceraldehyde-3-phosphate dehydrogenase (GAPDH) which catalyzes the first step of energy...

Published: 1/22/2026 | Inventor(s): Shanmugasundaram Ganapathy-Kanniappan

Keywords(s): Biologics, Cancers, Disease Indication, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

1 2 3 4